EUVIMEDEUVIMED entdecken
Open Access

Anti-TFAM antibodies link mitochondrial damage with antiphospholipid syndrome and thrombosis in SLE

Eduardo Gómez-Bañuelos, Alessandra Ida Celia, Maria Isabel Trejo-Zambrano, Jesus Aureliano Robles-De Anda, Merlin Paz, Shruti Chaturvedi, Fabrizio Conti, Cristiano Alessandri, Eleni Tiniakou, Daniel W Goldman, Robert A Brodsky, Michelle Petri und 1 weitere

Annals of the Rheumatic Diseases · 2025

DOI: 10.1016/j.ard.2025.04.015 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Annals of the Rheumatic Diseases, 2025. Verfasst von Eduardo Gómez-Bañuelos und 12 weiteren Autor:innen. Beteiligte Einrichtung: Division of Rheumatology, The Johns Hopkins University School of Medicine, Baltimore, MD, USA. Hauptthemen laut MEDLINE: Lupus Erythematosus, Systemic, Antiphospholipid Syndrome, Thrombosis, Autoantibodies. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 51 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIAID NIH HHS, NIAMS NIH HHS, National Institutes of Health National Institute of Allergy and Infectious Diseases.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

OBJECTIVES: Mitochondria are a source of autoantigens and damage-associated molecular patterns (DAMPs) in systemic lupus erythematosus (SLE). Nucleoids carrying TFAM (transcription factor A, mitochondrial) and mitochondrial DNA (mtDNA) are important DAMPs in SLE. While mtDNA has been associated with anti-double-stranded (ds)DNA antibodies and type I interferon (IFN-I), the immunogenic role of TFAM in SLE pathogenesis is unknown. Here, we characterised the clinical and transcriptional phenotypes linked to anti-TFAM antibodies in SLE. METHODS: Anti-TFAM antibodies were discovered in an exploratory sample of 22 SLE patients and 9 healthy controls. To define the prevalence, clinical significance, and associations with transcriptional profiles and IFN levels, anti-TFAM antibodies were detected using enzyme-linked immunosorbent assay (ELISA) in 98 healthy controls and 158 SLE patients. Sera from patients with dermatomyositis, rheumatoid arthritis, and primary antiphospholipid syndrome (PAPS) were also tested. RESULTS: Anti-TFAM antibodies were discovered in patients with SLE while analysing neutrophil autoantigens and confirmed by ELISA and immunoblotting. One-third of SLE patients (48/158) were positive for anti-TFAM antibodies. Unlike anti-dsDNA antibodies, anti-TFAM antibodies were not associated with disease activity or the IFN signature. Instead, anti-TFAM antibodies were associated with thrombosis, antiphospholipid syndrome (APS) (odds ratio [OR], 2.9 and 5.4, respectively), thrombosis-associated transcriptional profiles, and elevated IFN-III. Anti-TFAM antibodies were also found in PAPS, supporting their role in APS but not SLE pathogenesis. Lupus anticoagulant increased the risk of thrombosis associated with anti-TFAM antibodies (OR, 8.71), indicating they are markers of independent prothrombotic pathways. CONCLUSIONS: Anti-TFAM antibodies identify a distinct clinical and transcriptional disease subset associated with mitochondrial damage, thrombosis, and APS in SLE.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Lupus Erythematosus, SystemicAntiphospholipid SyndromeThrombosisAutoantibodiesMitochondriaTranscription FactorsDNA-Binding ProteinsMitochondrial ProteinsHumansFemaleMaleAdultMiddle AgedCase-Control StudiesYoung AdultInterferon Type IAutoantigensEnzyme-Linked Immunosorbent Assay

Substanzen

AutoantibodiesTranscription FactorsDNA-Binding ProteinsTFAM protein, humanMitochondrial ProteinsInterferon Type IAutoantigens

Autor:innen und Institutionen

  • Division of Rheumatology, The Johns Hopkins University School of Medicine, Baltimore, MD, USA.
  • Division of Rheumatology, The Johns Hopkins University School of Medicine, Baltimore, MD, USA; Rheumatology Unit, Department of Clinical Internal, Anesthesiological and Cardiovascular Sciences, Sapienza University of Ro…
  • Division of Hematology, The Johns Hopkins University School of Medicine, Baltimore, MD, USA.
  • Rheumatology Unit, Department of Clinical Internal, Anesthesiological and Cardiovascular Sciences, Sapienza University of Rome, Rome, Italy.
  • Division of Rheumatology, The Johns Hopkins University School of Medicine, Baltimore, MD, USA. Electronic address: andrade@jhmi.edu.

Förderung

  • NIAID NIH HHS
  • NIAMS NIH HHS
  • National Institutes of Health National Institute of Allergy and Infectious Diseases
  • Sapienza Università di Roma
  • National Institute of Arthritis and Musculoskeletal and Skin Diseases
  • Jerome L Greene Foundation
  • Aid for Cancer Research
  • National Institutes of Health

Zitieren

APA

Gómez-Bañuelos, E., Celia, A. I., Trejo-Zambrano, M. I., Robles-De Anda, J. A., Paz, M., Chaturvedi, S., Conti, F., Alessandri, C., Tiniakou, E., Goldman, D. W., Brodsky, R. A., Petri, M., & Andrade, F. (2025). Anti-TFAM antibodies link mitochondrial damage with antiphospholipid syndrome and thrombosis in SLE. Annals of the Rheumatic Diseases. https://doi.org/10.1016/j.ard.2025.04.015

Vancouver

Gómez-Bañuelos E, Celia AI, Trejo-Zambrano MI, Robles-De Anda JA, Paz M, Chaturvedi S, et al. Anti-TFAM antibodies link mitochondrial damage with antiphospholipid syndrome and thrombosis in SLE. Annals of the Rheumatic Diseases. 2025. doi:10.1016/j.ard.2025.04.015

BibTeX
@article{GmezBauelos2025,
  author = {Gómez-Bañuelos, Eduardo and Celia, Alessandra Ida and Trejo-Zambrano, Maria Isabel and Robles-De Anda, Jesus Aureliano and Paz, Merlin and Chaturvedi, Shruti and Conti, Fabrizio and Alessandri, Cristiano and Tiniakou, Eleni and Goldman, Daniel W and Brodsky, Robert A and Petri, Michelle and Andrade, Felipe},
  title = {Anti-TFAM antibodies link mitochondrial damage with antiphospholipid syndrome and thrombosis in SLE},
  journal = {Annals of the Rheumatic Diseases},
  year = {2025},
  doi = {10.1016/j.ard.2025.04.015}
}
Kostenlos starten →